Marshall Wace North America’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Marshall Wace North America’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,956	Closed	-$301K	–	1701
2019 Q1	$301K	Buy	5,956 +2,182	+58%	+$97.1K	﹤0.01%	902
2018 Q4	$152K	Buy	+3,774	New	+$194K	﹤0.01%	1009
2018 Q3	–	Sell	-89,760	Closed	-$6.79M	–	1453
2018 Q2	$6.79M	Buy	89,760 +38,338	+75%	+$2.41M	0.04%	438
2018 Q1	$2.71M	Sell	51,422 -29,915	-37%	-$1.74M	0.01%	728
2017 Q4	$4.34M	Buy	+81,337	New	+$4.53M	0.02%	616

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace North America's EGRX Position: Q2 2019 in Review

Marshall Wace North America sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 5,956 shares — an estimated $301K sold.

Marshall Wace North America first reported a position in EGRX in Q4 2017 and held it in 5 quarters. The position peaked at $6.79M in Q2 2018. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Marshall Wace North America reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Marshall Wace North America sold 5,956 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $301K.
Marshall Wace North America first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 5 quarters.
Marshall Wace North America's Eagle Pharmaceuticals, Inc. position peaked at $6.79M in Q2 2018.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.